Focus: BALT is a medical device manufacturer specializing in interventional neurovasculature products for treating aneurysms, stroke, and hemorrhagic conditions. The company operates from Irvine, CA with a focused product portfolio addressing critical neurovascular indications.
Profile data last refreshed 51m ago · AI intelligence enriched 2w ago
Stable — net -3 jobs in 30d
5 added, 8 removed. Backfill posture.
BALT is a specialized device-stage company offering niche expertise in neurovascular intervention, but limited transparency on financials and clinical maturity warrants due diligence on cash runway and product approval timelines before committing.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for BALT
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from BALT's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Adagio Medical Holdings, Inc. (ADGM) (CIK 0002006986) — EXHIBIT 99.1
EXHIBIT 99.1
8-K Filing: TREX CO INC (TREX) (CIK 0001069878) — EX-99.2
EX-99.2
Pharmacy market in Rīga belongs to handful of merchants / Article - LSM
Pharmacy market in Rīga belongs to handful of merchants / Article LSM
DOJ Bribery Declination Offers Blueprint for Global Medtech M&A - Bloomberg Law News
DOJ Bribery Declination Offers Blueprint for Global Medtech M&A Bloomberg Law News
Top 10 International Anti-Corruption Developments for March 2026 - JD Supra
Top 10 International Anti-Corruption Developments for March 2026 JD Supra
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Sociodemographic and psychosocial risk factors of railway suicide a mixed-methods study combining data of all suicide decedents in the Netherlands with data from a psychosocial autopsy study.
Social media use of adolescents who died by suicide: lessons from a psychological autopsy study.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo